TIM-3 blockade enhances IL-12-dependent antitumor immunity by promoting CD8+ T cell and XCR1+ dendritic cell spatial co-localization
Abstract
T cell immunoglobulin and mucin domain containing−3 (TIM-3) blocking antibodies are currently being evaluated in clinical trials for solid and hematological malignancies. Despite its identification on T cells, TIM-3 is predominantly expressed by myeloid cells, including XCR1+ type I conventional dendritic cells (cDC1s). We have recently shown that TIM-3 blockade promotes expression of CXCR3 chemokine ligands by tumor cDCs, but how this drives a CD8+ T cell-dependent response to therapy is unclear.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jan 01, 2022
- Source ID
- 10.1136/jitc-2021-003571
Entities
People
- Agnieszka Kasprzak
- Alexis Onimus
- Alvaro De Mingo Pulido
- Alycia Gardner
- Brian Ruffell
- Jose R Conejo-Garcia
- Katarzyna A Rejniak
- Kay Hänggi
- Sarah Bazargan
Organizations
- H. Lee Moffitt Cancer Center & Research Institute
- National Cancer Institute
- Swiss National Science Foundation
- United States Department of Defense